AstraZeneca plc stock (GB0009895292): Jefferies maintains Buy rating

Jefferies analyst Michael Leuchten kept his Buy recommendation on AstraZeneca plc intact with a target price of GBX 18,000, as reported on May 13, 2026. The stock traded at 13,733 GBX amid a slight daily dip.

Jefferies analyst Michael Leuchten maintained his Buy rating on AstraZeneca plc shares on May 13, 2026, keeping the target price steady at GBX 18,000, according to MarketScreener as of 05/13/2026. This reaffirmation comes as the stock showed a 5-day gain of 1.59% despite a 0.11% drop to 13,733 GBX on the London Stock Exchange.

The shares of AstraZeneca plc, listed on NYSE as AZN for US investors, closed at $184.54 on May 12, 2026, up 1.47% from the prior session, per WallStreetZen as of 05/12/2026. This provides dual-listing exposure relevant to US retail portfolios tracking global pharma leaders.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AstraZeneca PLC
• Sector/industry: Pharmaceuticals
• Headquarters/country: United Kingdom
• Core markets: Global, with strong US presence
• Key revenue drivers: Oncology, rare diseases, respiratory
• Home exchange/listing venue: London Stock Exchange (AZN.L), NYSE (AZN)
• Trading currency: GBX (LSE), USD (NYSE)

AstraZeneca plc: core business model

AstraZeneca plc develops and commercializes prescription medicines across oncology, rare diseases, and bioPharmaceuticals globally. The company focuses on innovative therapies addressing unmet medical needs, with a portfolio spanning small molecules, biologics, and cell therapies. Headquartered in Cambridge, UK, it operates in over 100 countries, leveraging a network of research sites and partnerships.

Revenue stems primarily from blockbuster drugs like Enhertu in oncology and Symbicort in respiratory care. AstraZeneca plc invests heavily in R&D, spending billions annually to advance its pipeline, which includes candidates in antibody-drug conjugates and next-generation vaccines. This model supports sustained growth amid patent cliffs through diversified revenue streams.

Main revenue and product drivers for AstraZeneca plc

Oncology represents the largest revenue contributor, driven by products such as Tagrisso and Imfinzi, generating billions in annual sales as reported in recent financials. Rare disease therapies like Ultomiris and Evusheld bolster margins with high pricing power. For the trailing period published in 2026 data, revenue reached $60.44 billion with earnings of $10.39 billion, per WallStreetZen as of 05/12/2026.

BioPharmaceuticals, including cardiovascular and respiratory drugs, provide stability. Key drivers include Farxiga for diabetes and heart failure, contributing significantly to US market penetration. Dividend yield stands at 3.45%, appealing to income-focused US investors tracking NYSE AZN.

Industry trends and competitive position

The global pharmaceutical sector faces pressures from biosimilar competition and regulatory scrutiny, yet oncology demand surges with aging populations. AstraZeneca plc holds a strong position via its ADCs leadership, competing with Roche and Pfizer. Its beta of 0.44 indicates lower volatility, suitable for defensive US portfolios.

Strategic acquisitions and partnerships enhance its pipeline, positioning AstraZeneca plc amid trends like precision medicine. Market cap of $285.85 billion underscores scale, with P/E at 27.5x reflecting growth expectations.

Why AstraZeneca plc matters for US investors

NYSE listing as AZN offers US investors direct access to a FTSE 100 pharma giant with substantial US revenue exposure from drugs like Tagrisso. Amid healthcare spending growth, AstraZeneca plc's innovations align with US market dynamics, providing diversification beyond domestic biotech.

AstraZeneca plc: recent analyst sentiment

Jefferies' reaffirmation highlights confidence in AstraZeneca plc's trajectory. Broader metrics like GF Score of 87/100 from GuruFocus signal robust financial health as of recent assessments.

Conclusion

AstraZeneca plc continues to draw analyst support amid stable trading and strong fundamentals. With Jefferies upholding its Buy view and NYSE shares gaining recently, the company maintains momentum in key therapeutic areas. US investors gain exposure through AZN to global pharma trends, though market dynamics warrant ongoing monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.